Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|October 2, 2001
- Pharmaceutical Technology-10-02-2001
- Volume 25
- Issue 10
Outsourcing Outlook
Author(s)Jim Miller
Recovery of the contract services industry picked up steam in the quarter ending 30 June 2001.
Advertisement
Articles in this issue
almost 25 years ago
Hydrogels for the Controlled Release of Pharmaceutical Proteinsalmost 25 years ago
Near-Infrared Inspection Complements Other QC Systemsalmost 25 years ago
Safety and Manufacturing Standardsalmost 25 years ago
Current Status of the Oral Delivery of Insulinalmost 25 years ago
Laboratory Equipment Qualificationalmost 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited, Part Ialmost 25 years ago
360° Feedback - Improving the Selection Process All the Way AroundAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement